Centre Georges François Leclerc
Centre Georges François Leclerc
Dijon, France35 results · Page 1 of 2
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Study Aiming to Compare the Plasma Exposure of the Payload (Free-DXd) in Patients Treated by T-DXd for Locally Advanced or Metastatic Breast Cancer According to Their BMI. | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Phase 4 | 2026-10-08 | NCT07195344 | |
| Paclitaxel + Carboplatin + Durvalumab With or Without Oleclumab for Previously Untreated Locally Recurrent Inoperable or Metastatic TNBC | Neoplasm Metastasis, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder, triple-negative breast carcinoma | Active, not recruiting | Phase 1 / Phase 2 | 2026-10-07 | NCT03616886 | |
| Skipping Hormone Therapy in Low-Risk Early Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Phase 2 | 2026-10-05 | NCT07661927 | |
| Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i. | Advanced Breast Cancer; ER-positive Breast Cancer; ESR1 Gene Mutation; HER2-negative Breast Cancer | Recruiting | Phase 3 | 2026-08-24 | NCT06382948 | |
| ENCOrafenib With Binimetinib in bRAF NSCLC | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Phase 2 | 2026-08-11 | NCT04526782 | |
| Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, digestive system disorder, digestive system neoplasm, gastric cancer, gastric neoplasm, neoplasm, stomach disorder | Recruiting | Phase 3 | 2026-08-10 | NCT06731478 | |
| Study Investigating ASP3082 in Patients With Metastatic/Locally Advanced Non-small-cell Lung Cancer (NSCLC) and Pancreatic Ductal Adenocarcinoma (PDAC), With Biomarker Analysis to Characterize Response/Resistance | Neoplasm Metastasis, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, neoplasm | Recruiting | Phase 2 | 2026-08-05 | NCT07483983 | |
| Study on the Efficacy of Treatment by Radiotherapy and Pembrolizumab in Newly Diagnosed Metastatic Head & Neck Cancers | Head and Neck Neoplasms, Neoplasm Metastasis, Neoplasms by Histologic Type, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, carcinoma, epithelial neoplasm, head and neck squamous cell carcinoma, neoplasm, squamous cell carcinoma, squamous cell neoplasm | Recruiting | Phase 3 | 2026-07-31 | NCT04747054 | |
| SPECT-CT Guided ELEctive Contralateral Neck Treatment in Lateralized Oropharyngeal Cancer | Cancer of Oropharnyx, Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Otorhinolaryngologic Neoplasms, Pharyngeal Diseases, Stomatognathic Diseases, carcinoma, epithelial neoplasm, head and neck cancer, head and neck squamous cell carcinoma, neoplasm, oropharyngeal carcinoma, oropharynx squamous cell carcinoma, otorhinolaryngologic disease, squamous cell carcinoma | Not yet recruiting | Not applicable | 2026-07-21 | NCT07241273 | |
| PARa-aOrtic LymphAdenectomy in Locally Advanced Cervical Cancer | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, Uterine Cervical Neoplasms, adenocarcinoma, adenosquamous carcinoma, carcinoma, cervical carcinoma, cervix disorder, epithelial neoplasm, female reproductive system disorder, female reproductive system neoplasm, mixed neoplasm, neoplasm, uterine disorder | Recruiting | Phase 3 | 2026-07-07 | NCT05581121 | |
| Neoadjuvant Atezo, Adjuvant Atezo + Beva Combined With RF Ablation of Small HCC: a Multicenter Randomized Phase II Trial | Digestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, carcinoma, epithelial neoplasm, hepatocellular carcinoma, liver disorder, neoplasm | Active, not recruiting | Phase 2 | 2026-06-22 | NCT04727307 | |
| Arm Swelling Occurence in Breast Cancer Patients With Nodal Radiotherapy: Impact of Informing Them of AI-predicted Risk | Neoplasms by Site, Skin and Connective Tissue Diseases, Unilateral Breast Neoplasms, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Not applicable | 2026-05-19 | NCT07187726 | |
| Neoadjuvant and Adjuvant Ribociclib and ET for Clinically High-risk ER+ and HER2- Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 2 | 2026-05-14 | NCT05296746 | |
| Evaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma | Digestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, carcinoma, epithelial neoplasm, hepatocellular carcinoma, liver disorder, neoplasm | Recruiting | Phase 2 | 2026-03-16 | NCT05528952 | |
| Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, estrogen-receptor positive breast cancer, neoplasm, skin disorder | Active, not recruiting | Phase 3 | 2026-02-12 | NCT02947685 | |
| Multimodal Immune Characterization of RAre Soft Tissue Sarcoma - MIRAS Project From SARRA (SARcome RAre) Project of the French Sarcoma Group | Neoplasms by Histologic Type, Neoplasms, Connective and Soft Tissue, alveolar soft part sarcoma, clear cell sarcoma, connective tissue neoplasm, desmoplastic small round cell tumor, epithelioid hemangioendothelioma, hemangioendothelioma, hemangioma, low grade fibromyxoid sarcoma, myomatous neoplasm, neoplasm, neoplasm with perivascular epithelioid cell differentiation, sarcoma, vascular cancer | Recruiting | Not applicable | 2026-02-10 | NCT03967834 | |
| A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Histologic Type, Neoplasms, Connective and Soft Tissue, connective tissue neoplasm, digestive system disorder, digestive system neoplasm, gastrointestinal stromal tumor, neoplasm | Active, not recruiting | Phase 3 | 2026-02-05 | NCT03673501 | |
| Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1) | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Phase 1 / Phase 2 | 2026-01-29 | NCT03974022 | |
| Evaluation of UCPVax Vaccine +/- Pembrolizumab Combined With Standard Treatment as Adjuvant Therapy in Patients With Unmethylated MGMT Glioblastoma | Primary Glioblastoma | Not yet recruiting | Phase 2 | 2026-01-16 | NCT07347210 | |
| A Phase II Study Assessing Stereotactic Radiotherapy in Therapeutic Strategy of Oligoprogressive Renal Cell Carcinoma Metastases | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, benign urinary system neoplasm, carcinoma, epithelial neoplasm, kidney cancer, kidney disorder, neoplasm, renal cell carcinoma, urinary system disorder | Recruiting | Phase 2 | 2026-01-13 | NCT04299646 | |
| Hepatic Arterial Infusion of Gemcitabine-oxaliplatin for Second-line Therapy in Non-metastatic Unresectable Intra-hepatic Cholangiocarcinoma | Cholangiocarcinoma Non-resectable; Non-metastatic | Recruiting | Phase 2 | 2026-01-05 | NCT03364530 | |
| Definition for the Assessment of Time-to-event Endpoints in CANcer Trials (DATECAN-1) | cancer, neoplasm | Active, not recruiting | Not stated | 2025-12-10 | NCT03676010 | |
| Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI | Neoplasm Metastasis, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Connective and Soft Tissue, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, adenocarcinoma, adrenal cortex disorder, adrenal cortex neoplasm, adrenal gland cancer, adrenal gland disorder, carcinoma, carcinoma of the ampulla of vater, duodenal adenocarcinoma, endocrine system disorder, epithelial neoplasm, gastric adenocarcinoma, malignant endocrine neoplasm, neoplasm, neuroendocrine carcinoma, neuroendocrine neoplasm, pancreatic adenocarcinoma, primitive neuroectodermal tumor, sarcoma, small intestine adenocarcinoma | Recruiting | Phase 2 | 2025-12-02 | NCT06333314 | |
| Treatment With Tucatinib in Patients With an Isolated Brain Progression of a Metastatic Breast Cancer | Metastatic Breast Cancer With a Isolated Brain Progression | Active, not recruiting | Phase 2 | 2025-11-17 | NCT05041842 | |
| LONsurf and G-CSF Use: Being On A Right Dose-intensity to Optimize Treatment Efficacy | Cytopenia, Digestive System Diseases, Digestive System Neoplasms, Hemic and Lymphatic Diseases, Neoplasms by Site, agranulocytosis, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, hematologic disorder, intestinal disorder, leukocyte disorder, leukopenia, neoplasm, neutropenia, rectal disorder | Active, not recruiting | Phase 2 | 2025-08-19 | NCT04166604 |